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Recent evidence suggests that injury to the renal vasculature
may play an important role in the pathogenesis of both early
and chronic ischemic acute kidney injury (AKI). Established
and new data support the suggestion that vascular injury, in
particular, endothelial cell injury, participates in the extent
and maintenance of AKI by pathways that are related to
vascular tone. Early alterations in peritubular capillary blood
flow during reperfusion has been documented and
associated with loss of normal endothelial cell function,
which can be replaced pharmacologically or with cell
replacement interventions. Distorted peritubular capillary
morphology is associated with loss of barrier function that
may contribute to early alterations in vascular stasis. In
addition, ischemia induces alterations in endothelial cells that
may promote inflammation and procoagulant activity, thus
contributing to vascular congestion. Reductions in
microvasculature density may play a critical part in the
progression of chronic kidney disease following initial
recovery from ischemia/reperfusion-induced AKI. The exact
nature of how capillary loss alters renal function and
predisposes renal disease is thought to be due at least in part
to hypoxia. Finally, the loss of endothelial cell function may
represent an important therapeutic target in which nitric
oxide, vascular trophic support, and/or endothelial
progenitor cells may show potential importance in
ameliorating the acute and/or chronic effects of ischemic AKI.
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Acute kidney injury (AKI) has remained a significant health
care concern with high mortality rates for several decades.
Ischemia due to hypotension or sepsis is the most common
cause of human AKI.1 Despite the central role of tubular
injury clearly evident in this syndrome, the hallmark feature
of AKI is a reduction in glomerular filtration rate. Therefore,
by its very essence, AKI is a phenomenon of altered renal
hemodynamics. The renal vasculature following ischemia is
influenced by factors deriving from the circulation and/or
stressed renal parenchyma. Many studies have focused on the
activation of various vasoactive pathways as a consequence of
injury.2,3 There is now an increasingly keen interest in the
effect of direct injury to the renal vasculature and its
potential role in the pathogenesis of AKI. Therefore, the
purpose of this brief review is to highlight recent advances
related to renal vasculature injury in the setting of AKI.
Emphasis will be placed on alterations in endothelial
structure and function and the evidence that these may
influence pathogenesis, based primarily on models of
ischemia. Further consideration will be given towards a
potential link between injured microvasculature and chronic
renal function as a basis for the development of chronic
kidney disease (CKD).
TUBULAR AND HEMODYNAMIC CONSEQUENCES IN MODELS
OF AKI
AKI and recovery has been studied in animal models
following ischemia/reperfusion (I/R) brought about by artery
clamping or infusion of vasoactive compounds.4,5 In rats,
following renal ischemia, there is an immediate increase in
renal vascular resistance and it has been recognized for some
time that therapies which reduce renal vascular resistance
diminish the extent of injury resulting from I/R.6–8 Altera-
tions in renal vascular resistance may result from the activity
of injured neighboring tubules before the manifestation of
tubular death and may be related to altered prostaglandin
synthesis, the generation of reactive oxygen species, or
activation of inflammatory pathways that are caused by
tubular responses to hypoxia. These pathways, and others,
have been described previously in recent excellent reviews.3
The resultant reduction in blood flow exacerbates hypoxia
and ultimately contributes to abundant cell death in the outer
medullary tubules. Sutton et al.2 have referred to this critical
period of altered vascular function as the ‘extension phase’
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and suggested that this may represent an important
therapeutic window in preserving the kidney from prolonged
organ failure and/or death.
Vascular damage as a mediator of early or sustained AKI
I/R damages the renal vasculature and compromises renal
function; this viewpoint has received increasing attention in
the last several years.2,9–11 Injury to the vasculature can
compromise renal function in a number of ways by
influencing vascular reactivity, altering capillary barrier
function, and modulating inflammatory and coagulation
pathways; any or all of these may prolong the underperfused
state of the kidney and exacerbate renal injury following I/R.
Studies by Conger et al.5 were among the first to highlight
intrinsic alterations in vascular function following I/R injury;
these investigators demonstrated that post-ischemic rat
kidneys do not autoregulate blood flow and, in fact, manifest
vasoconstriction in response to decreased renal perfusion
pressure. This occurred even 1 week following recovery from
I/R when total renal blood flow had returned to baseline
values. Morphological evidence of injury in endothelial cells
and smooth muscle cells was present up to 7 days following I/
R, induced by renal artery clamping or norepinephrine
infusion. The increased constrictor responses could be
blocked by Ca2þ antagonists.12 The loss of normal
endothelial nitric oxide synthase (NOS) function was
demonstrated by a loss of vasodilator responses to acetylcho-
line and bradykinin.12 This reduction in normal endothelial
function does not appear to be the result of the loss of
endothelial NOS (eNOS) protein levels, but may result from
inhibition of enzyme activity since bradykinin failed to
produce a measurable levels NO in post-ischemic kidneys
measured electrochemically. This occurred despite an overall
increase in baseline renal NO content that was thought to be
the result of inducible NOS (iNOS) activity in the tubular
system (for review see Goligorsky et al.13). Although still
unclear, NO production from eNOS may be impaired at the
level of enzyme activity or modified by reactive oxygen
species to impair normal vasodilatory activity.14
The impairment of normal endothelial dependent vaso-
dilator activity has prompted investigators to develop
strategies to enhance endothelial function in the setting of
AKI. For example, administration of L-arginine, NO-donor
molsidomine, or the eNOS cofactor tetrohydrobiopterin can
preserve medullary perfusion and attenuate AKI induced by
I/R;15–19 conversely the administration of No-nitro-L-arginine
methyl ester, an NO blocker, has been reported to aggravate
the course of AKI following I/R injury.20 Although clearly
important, these pharmacological studies make it difficult to
assess the contribution of eNOS impairment in the overall
course of reduced renal function following I/R.
To more thoroughly address the role of endothelial cells
following I/R, recent studies have focused on rapid changes in
blood flow in the initiation or maintenance of injury in the
setting of I/R. Using in vivo video microscopy to monitor
capillary perfusion, Yamamoto10 reported that renal perfu-
sion in peritubular vessels was compromised within minutes
of reperfusion and is characterized by sluggish and
occasionally retrograde blood flow. Using a similar model,
Brodsky et al.,9 demonstrated that implantation of endothe-
lial cells to athymic nude rats or other cells which harbor the
eNOS gene protected against this early compromise in blood
flow, suggesting that endothelial dysfunction contributes to
an early compromise in renal hemodynamics.
An intriguing aspect of these studies relates to the
possibility that cell-based therapies that replace endothelial
cell function may have benefits in AKI. Arriero et al.21
propagated adult stem cells derived from skeletal muscle of
Tie-2 GFP mice; in vitro cell expansion led to the isolation of
an endothelial cell phenotype defined by expression of GFP
and other endothelial markers such as Tie-2, flt, flk, and
eNOS. Administration of these cells at the time of reperfusion
into the aorta through a carotid catheter generated short-
term engraftment into the renal vasculature and short-term
protection of renal blood flow after I/R injury. It must be
pointed out that Togel et al.22 has shown that adult
mesenchymal stem cells derived from bone marrow are
protective in rats following I/R. However, although many of
these cells have endothelial characteristics, they are only
transiently found within the kidney and do not appear to
engraft. Thus, it is suggested that that the protection offered
is humoral. Recently, this group published additional studies
suggesting that these types of mesenchymal stem cell may
influence renal vascular activity by increasing trophic support
for the renal endothelial cells, thereby preserving function.23
In addition to alterations in eNOS, at least one other
prominent vasoactive factor of endothelial origin has received
considerable attention in the setting of I/R. The potent
vasoconstrictor endothelin is elevated in peritubular capillary
endothelial cells following reperfusion injury and pharma-
cological inhibition of endothelin significantly reduces
functional renal injury in the setting of ischemia reperfu-
sion.24,25 However, the overall importance is difficult to assess
since the protection conferred by antagonists following I/R is
generally modest.26,27
Altered endothelial function probably also mediates
inflammation, a hallmark feature of I/R injury that has been
the subject of numerous studies.2,3,28 Monocyte and macro-
phage adhesion is evident as early as 2 h post-I/R.28,29 This
adhesion contributes to erythrocyte trapping and hemostasis,
prolonging the reduction in renal blood flow and exacerbat-
ing tubular injury. I/R injury itself increases the capillary
expression of a number of leukocyte adhesion molecules
including P- and E-selectin and intercellular adhesion
molecule; treatments geared toward reducing endothelial–-
leukocyte interactions by inhibiting these molecules protect
against renal damage in I/R-induced AKI.29–31
Renal I/R injury alters cytoskeletal organization of small
arterioles and endothelial cells that may relate to the
presentation of surface expression molecules.2,11,32 It has
also been suggested that such alterations in cellular
morphology disrupt endothelial cell tight junctions as
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indicated by the breakdown of VE-cadherin in microvessels
of the kidney. In vivo two-photon imaging demonstrated a
loss of capillary barrier function within 2 h of reperfusion as
evidenced by leakiness of high molecular weight dextrans
(4300 000 Da) into the interstitial space.11 Breakdown of
barrier function may be the result of matrix metalloprotei-
nase-2 or -9 activation.33 The potential ramifications of
endothelial leakiness in the course of AKI are unclear.
Increased edema resulting from leakiness may compromise
renal perfusion by compressing peritubular capillaries and/or
increasing hemoconcentration and exacerbating erythrocyte
trapping.2
The formation of microthrombi have been described in
renal I/R models as well as in renal transplant biopsies.2,34
Whether endothelial cell damage promotes thrombus for-
mation in renal I/R remains to be clearly established as there
have been few studies that have directly investigated this
pathway.
VASCULAR DAMAGE AS A MEDIATOR OF CHRONIC
ALTERATIONS IN RENAL FUNCTION FOLLOWING AKI
Following AKI, the complete return of renal function is
generally expected if the patient survives the initial insult.
However, there a growing appreciation for the chronic effects
of AKI in a number of animal models as well as several
clinical conditions in which long-term follow-up studies have
been carried out.35 For example, recent data suggest that up
to 13 % of patients, following AKI, progress to end-stage
renal disease within 3 years; if a pre-existing renal disease is
present, progression to end-stage rises to 28% within the
same time period (P Eggers, NIDDK, personal communica-
tion, 2006). Moreover, pediatric patients following AKI have
a high predisposition to progressive renal failure and
hypertension,35,36 while injury in the setting of transplanta-
tion (i.e., delayed graft function) represents an independent
risk factor for graft survival and the development of post-
transplant hypertension.35,37 These observations suggest that
acute injuries to the kidney predispose chronic complica-
tions. Work from our laboratory has led to the suggestion
that peritubular capillaries are chronically compromised
post-ischemia and may contribute to the long-term compli-
cations observed following the initial recovery from AKI.
Using a microfil technique, we demonstrated that post-
ischemic rat kidneys manifested consistent reductions in
microvessel density following uncomplicated recovery from
I/R injury at 4, 8, and 40 weeks post-surgery.35,38 In these
original studies, vascular dropout by microfil analysis was
assessed as reductions in percent surface area on histology
sections or with an index comprising intersections of filled
structures across arbitrary grid lines; both of these yielded
B30–50% reductions in density.35 Although there is potential
concern with this method, since impaired perfusion could
reduce the ability to visualize existing vessels, other
approaches utilize immunohistochemistry of endothelial
markers to assess vascular density (e.g., CD31/platelet–en-
dothelial cell adhesion molecule, rat endothelial cell antigen)
reliably. In the setting of renal I/R, we have observed a
comparable percentage in the reduction of vessels utilizing
platelet–endothelial cell adhesion molecule staining (D Basile,
unpublished data) suggesting good agreement between
different methodologies. The reduction in blood-vessel
density following I/R is a seemingly simple observation but
reveals an important element of the renal response to I/R;
although the renal tubular system has impressive capacity for
regeneration, the renal vascular system lacks comparable
regenerative potential.
FUNCTIONAL CONSEQUENCES OF CAPILLARY LOSS
FOLLOWING ACUTE RENAL FAILURE
Among the questions worth considering is the determination
of the functional consequences of peritubular capillary
dropout following AKI. CKD following ischemic AKI in rats
is characterized by the development of interstitial fibrosis and
proteinuria that develops with prolonged recovery times
following I/R.35 There is an emerging view that chronic
hypoxia, induced by loss of peritubular capillaries or
increased vascular resistance, may result in the development
of tubulointerstitial fibrosis in renal diseases of diverse
etiologies, representing a potential common pathway for
disease progression. Hypoxia stimulates several fibrogenic
activities including the molecular regulation of fibrogenic
factors such as transforming growth factor (TGF)-b and
extracellular matrix genes.39,40 The fibrosis is progressive in
nature since the deposition of interstitial scars increases the
distance for diffusion to the renal parenchyma and creates
more severe hypoxia and fibrosis.40,41
Studies from our laboratory have attempted to address the
potential role of hypoxia post-I/R. Using the hypoxia-
sensitive marker pimondizole, we demonstrated that kidneys
of rats following recovery from acute renal failure are more
hypoxic, particularly in the outer medulla, than those of
corresponding sham-operated control rats.42 I/R injury
carried out with simultaneous unilateral nephrectomy
worsened hypoxia following I/R and hastened the develop-
ment of secondary renal disease. Moreover, treatment of
post-ischemic animals with L-arginine, beginning at day 3
following injury, increased renal blood flow, diminished
hypoxia, and attenuated the development of secondary renal
scarring and proteinuria that occurs with prolonged recovery
times.42
The feature of peritubular capillary dropout is shared by
other models of progressive renal disease leading to
interstitial fibrosis such as models induced by angiotensin
II infusion, cyclosporine, 5/6 nephrectomy, aging, unilateral
ureteral obstruction, and even glomerulonephritis; some of
these have also been characterized by increased hypox-
ia.39,43–49 In these studies and ours described above, the
primary method used to evaluate hypoxia was based on the
incorporation of pimonidizole; this compound is reported to
form adducts at ppO2 below 10 mm Hg50 and the resultant
adducts identified by immunohistochemical evaluation.
Although simple, the method is not ideal since it is
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nonquantitative and allows the potential incorporation of
histochemical artifacts. Quantitative methodologies such as
the use of oxygen electrodes have not been widely applied in
these models, perhaps, because comparisons between animals
using small probes (and hence limited sampling volume)
would be tenuous. Functional-imaging techniques may be
helpful to evaluate renal oxygenation quantitatively. For
example, blood oxygen level-dependent magnetic resonance
imaging utilizes alterations in oxygenated hemoglobin to
induce paramagnetic shifts in surrounding protons51 and
may be useful to evaluate renal oxygenation and/or blood
flow noninvasively. This approach was recently utilized to
evaluate impaired renal oxygenation in patients with chronic
renal allograft dysfunction.52 In summary, although current
data using pimonidizole are consistent with increased
hypoxia in the setting of vascular dropout, better correlation
with quantitative methods, specifically those with clinical
utility, should be at the forefront of future investigation.
In addition to hypoxia-induced scarring, several of these
models are also characterized by susceptibility to sodium-
dependent hypertension. Similarly, we have also demon-
strated that rats recovering from acute renal failure are prone
to develop sodium-dependent hypertension after their initial
recovery, which is associated with a profoundly accelerated
secondary CKD (preliminary unpublished data). These
observations suggest that recovery from AKI compromises
normal sodium excretion. The mechanism of altered sodium
handling following initial recovery from AKI is unclear and
future studies will be geared toward understanding whether
these alterations are due to effects on the renal vasculature. It
is possible that these results relate to reductions in renal
medullary blood flow that have been associated with sodium-
dependent hypertension and are presumed to shift the
pressure–natriuresis relationship towards higher arterial
blood pressures.39,53
WHAT IS THE CAUSE OF CAPILLARY LOSS FOLLOWING ACUTE
RENAL FAILURE?
An additional important yet unresolved question relates to
the mechanism by which blood-vessel loss occurs in the
setting of I/R. Several possibilities exist, including the idea
that acute injury results in death of endothelial cells via
apoptotic or necrotic mechanisms. Clearly, factors associated
with ischemic injury such as TGF-b and tumor necrosis
factor-a can stimulate apoptosis in endothelial cells54,55 and
this possibility has been suggested in renal transplant.56,57
Although these represent probable scenarios, it must be
emphasized that as of yet, there have been no published
studies demonstrating apoptosis following renal I/R in
endothelial cells.
Endothelial cells may also transdifferentiate into fibro-
blast/myofibroblasts; this process is referred to as endo-
thelial–mesenchymal transition (endo-MT). Evidence for
endo-MT is derived from in vitro studies in which cultured
endothelial cells express markers of myofibroblasts (e.g.,
smooth muscle actin) or from in vivo data in which vascular
cells display markers of both endothelial and mesenchymal
cells simultaneously. Recent evidence suggests that this
process occurs during development and following injury to
the vasculature. In mouse kidney, NOS inhibition resulted in
peritubular capillaries staining positively for both endothelial
markers as well as smooth muscle actin suggesting possible
endo-MT.58–60 Endo-MT has similarities to epithelial–
mesenchymal transition, but has received relatively little
attention by comparison. Like epithelial–mesenchymal transi-
tion, endo-MT is suggested to be stimulated by many
factors including TGF-b.60 Interestingly, immunoneutraliza-
tion of TGF-b following renal I/R in rats preserved blood-
vessel density and also diminished the number of interstitial
fibroblasts present in the post-ischemic kidney; this raises the
interesting possibility that TGF-b may promote blood-vessel
loss by inducing phenotypic transition to a fibroblastic
phenotype.61 Nevertheless, as is the case with cell death, the
potential that I/R injury may contribute to endo-MT has not
been formally addressed.
Regardless of the mechanism by which endothelial cells are
lost, a related and equally interesting question relates to the
lack of vascular repair following renal I/R. It is possible that
the humoral milieu post-ischemia may either promote vessel
loss and/or inhibit repair or regeneration following injury.
Consistent with this idea, we have shown evidence in favor of
a shift towards the inhibition of angiogenesis, rather than
vascular repair following acute injury. Recent studies from
our laboratory demonstrated that the classic angiogenic
factor, vascular endothelial cell growth factor (VEGF), is
inhibited in the post-ischemic kidney for up to 1 week
following I/R (D Basile, preliminary unpublished data); this
is in contrast to results of other investigators that have shown
no effect of I/R on VEGF mRNA at earlier time points and
transient (1 day) upregulation of VEGF protein.62,63 The
reduction of VEGF mRNA expression (or lack of induction)
following ischemia is intriguing. In vitro studies demonstrate
that VEGF mRNA expression is stimulated in tubular
epithelial cells in response to hypoxia.64 Despite this, the
reduction in VEGF expression following I/R is consistent
with several models of CKD associated with vascular
rarefaction and persistent hypoxia.40,45,65,66 In contrast to
studies using cultured proximal tubules, Kramer et al.67
exposed rats to hypoxia, which stimulated an increase in the
renal expression of erythropoietin mRNA but not VEGF
mRNA. Thus, it appears that the canonical signaling pathway
by which hypoxia stimulates VEGF in vitro is not operational
in the kidney in vivo. The discrepancy between VEGF
responsiveness in cultured kidney cells versus the in vivo state
is not well understood.
In addition to VEGF reduction, we have identified that
renal I/R increases the expression of a number of molecules
that inhibit VEGF activity including angiostatin68 and
a disintegrin and metalloproteinase with thrombospondin
motifs-1 (ADAMTS1) (preliminary data). Finally, and as
mentioned above, blockade of TGF-b, which is highly
expressed following I/R, tended to protect microvascular
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density following I/R.61 These results suggest that post-
ischemic humoral milieu of the kidney may impair
regeneration of the vasculature in contrast to the regenerative
potential of the tubular system. Current efforts are now
geared toward evaluating whether alteration in the post-
ischemic milieu can be shifted in favor of vascular repair to
preserve or restore capillary density and affect long-term
renal function.
Figure 1 illustrates a schematic diagram outlining the
potential implications of vascular injury in the setting of I/R.
Early alterations in endothelial function may exacerbate the
extent of renal injury and further compromise blood flow
post-I/R. Resolution of endothelial cells’ structure is asso-
ciated with a resolution in vascular tone and reversal of stasis.
Permanent alterations in renal function can be brought about
by alterations in endothelial cells that result in loss of
capillary numbers. Capillary loss results in alterations in renal
oxygenation and hemodynamics that predispose hyper-
tension and CKD. This perspective suggests that interven-
tions targeting endothelial function may be beneficial for
both short- and long-term recovery from AKI.
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Figure 1 | Putative model for the influence of vascular injury
in the setting of renal I/R. The illustration suggests that I/R injury
results in damage to both tubular epithelial and vascular cells.
Alteration in vascular function results from damage to endothelial
and smooth muscle cells that affect early blood flow and contribute
to reduced glomerular filtration rate (GFR) and continued injury to
the tubular epithelium. Reduction in peritubular capillary density is
associated with loss of endothelial cells through undetermined
mechanisms. Loss of trophic support or production of inhibitory
factors from the epithelium has been proposed. Alteration in capillary
structure increases hypoxia-mediated fibrosis and alters proper
hemodynamics that contribute to hypertension.
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